AI-designed lung drug hints at aging slowdown in IPF study
TL;DR Summary
A small 12-week trial of rentosertib, an AI-discovered drug for IPF, found blood protein changes and aging biomarkers that made participants appear biologically 3–4 years younger, strongest after four weeks at 30 mg twice daily; the results, published in Nature Biotechnology, are preliminary, based on 42 IPF patients, and do not prove real aging reversal. Larger, longer trials including non-IPF populations are needed; a Phase 3 study is underway in China.
- Drug developed for lung disease may slow biological aging in surprising ‘bonus’ Fox News
- Early Data Indicates an A.I.-Generated Drug Could Slow Aging The New York Times
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment Nature
- Insilico's IPF candidate rentosertib shows anti-aging promise FirstWord PHARMA
- AI-designed drug candidate reverses biological age in clinical study News-Medical
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
8 min
vs 9 min read
Condensed
96%
1,722 → 71 words
Want the full story? Read the original article
Read on Fox News